doi:10.3969/j.issn.1004-583X.2021.06.019

Abstract

CLC Number:

R692.31

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.06.019

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I6/569

References 38

[1]	张明超, 经艳, 郑男君, 等. 肾组织PLA2R抗原检测方法的建立和评估[J]. 中华肾脏病杂志, 2018, 34(5):385-386.
[2]	Ronco P, Debiec H. Anti-phospho1ipase A2 receptor antibodies and the pathogenesis of membranous nephropathy[J]. Nephron Clin Pract, 2014, 128(3/4):232-237. doi: 10.1159/000368588 URL
[3]	Beck LH, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21. doi: 10.1056/NEJMoa0810457 URL
[4]	方玲, 顾向明, 周泽红, 等. 两种方法检测血清抗磷脂酶A2受体抗体在膜性肾病中的应用分析[J]. 检验医学与临床, 2017, 14(15):2196-2198.
[5]	Corrado M, Maurizio B, Giovanni C, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy[J]. Clin J Am Soc Nephrol, 2012, 7(9):1-7. doi: 10.2215/CJN.12121111 URL
[6]	Zhang D, Zou J, Zhang C, et al. Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: A single center retrospective study from China[J]. Med Sci Monit, 2018, 24(1):5076-5083. doi: 10.12659/MSM.909815 URL
[7]	Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12(10):1-10. doi: 10.2215/CJN.11511116 URL
[8]	Vincenzo LI, Federico P, Alberto SR, et al. Routine immunohistochemical staining in membranous nephropathy: In situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain[J]. J Nephrol, 2018, 31(4):543-550. doi: 10.1007/s40620-018-0489-z URL
[9]	王述莲, 孙钧, 郑继伟, 等. 抗磷脂酶A2受体抗体表达在特发性膜性肾病人肾组织及血液中的检测价值[J]. 实用医学杂志, 2016, 32(3):434-436.
[10]	詹富国, 吴秀风, 许文燊, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病中的诊断价值[J]. 中国卫生标准管理, 2017, 8(18):110-111.
[11]	Radice A, Pieruzzi F, Trezzi B, et al. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases[J]. J Nephrol, 2018, 31(2):271-278. doi: 10.1007/s40620-017-0451-5 pmid: 29081027
[12]	Garcia-Vives E, Solé C, Moliné T, et al. Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis[J]. Lupus, 2019, 28(3):1-10.
[13]	许向青, 朱雪婧, 袁曙光, 等. M型磷脂酶A2受体及其抗体在乙肝病毒相关性膜性肾病中的临床意义[J]. 中南大学学报(医学版), 2016, 41(10):1064-1068.
[14]	Tian C, Li L, Liu T, et al. Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy[J]. Int Urol Nephrol, 2019, 51(8):1371-1377. doi: 10.1007/s11255-019-02146-w URL
[15]	蒋真斌, 蔡美顺, 董葆, 等. 适合中国人的抗磷脂酶A2受体抗体临界值的界定[J]. 中华肾脏病杂志, 2020, 36(5):379-384.
[16]	计蕾, 余慰, 钟雪. 特发性膜性肾病患者血清抗磷脂酶A2受体抗体与尿中IgG4检测的临床意义[J]. 中国免疫学杂志, 2018, 34(7):1050-1053+1058.
[17]	Huang B, Zhang Y, Wang L, et al. Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy[J]. Kidney Blood Press Res, 2019, 44(4):1-10. doi: 10.1159/000497806 URL
[18]	Wang Y, He YX, Diao TT, et al. Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy[J]. Oncotarget, 2018, 9(1):67-74. doi: 10.18632/oncotarget.19859 pmid: 29416596
[19]	詹富国, 吴秀风, 陈惠娟, 等. 三种实验室指标在膜性肾病中的诊断价值[J]. 中国卫生标准管理, 2017, 8(19):124-126.
[20]	Pang L, Zhang AM, Li HX, et al. Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study[J]. Medicine, 2017, 96(24):1-7.
[21]	Li C, Li H, Wen YB, et al. Analysis of predictive factors for immunosuppressive response in antiphospholipase A2 receptor antibody positive membranous nephropathy[J]. BMC Nephrol, 2018, 19(1):1-6. doi: 10.1186/s12882-017-0808-y URL
[22]	林伟锋, 李航, 李雪梅, 等. 抗磷脂酶A2受体抗体与特发性膜性肾病的关系[J]. 中华内科杂志, 2015, 54(9):783-788.
[23]	Han WW, Tang LJ, Kong XL, et al. Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy[J]. Exp Ther Med, 2019, 17(3):1825-1830.
[24]	Zhang Q, Huang B, Liu X, et al. Ultrasensitive quantitation of anti-phospholipase A2 receptor antibody as a diagnostic and prognostic indicator of idiopathic membranous nephropathy[J]. Sci Rep, 2017, 7(1):12049. doi: 10.1038/s41598-017-12014-1 URL
[25]	Wu X, Liu L, Guo Y, et al. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults[J]. Int J Nephrol Renovasc Dis, 2018, 11:241-247. doi: 10.2147/IJNRD URL
[26]	Kim YG, Choi YW, Kim SY, et al. Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy[J]. Am J Nephrol, 2015, 42(3):250-257. doi: 10.1159/000440983 URL
[27]	褚晓鑫, 徐秀, 何晓峰, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病缓解中的价值[J]. 2018(10):752-758.
[28]	Provatopoulou S, Kalavrizioti D, Stangou M, et al. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study[J]. Rom J Intern Med, 2018, 57(2):141-150.
[29]	Guo N, Cao Y, Dai H, et al. Anti-phospholipase A2 receptor (Anti-PLA2R) antibody in diagnosis and treatment of idiopathic membranous nephropathy: A single-center observational study in China[J]. Med Sci Monit, 2019, 25:9364-9368. doi: 10.12659/MSM.917732 URL
[30]	Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years[J]. PLoS One, 2017, 12(3):e0173201. doi: 10.1371/journal.pone.0173201 URL
[31]	Jung OY, Hee YS, Ki KD, et al. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J]. PLoS One, 2013, 8(4):e62151. doi: 10.1371/journal.pone.0062151 URL
[32]	Dong D, Fan TT, Wang YY, et al. Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis[J]. BMC Nephrol, 2019, 20(1):444. doi: 10.1186/s12882-019-1638-x pmid: 31791262
[33]	Liang Y, Wan J, Chen Y, et al. Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: A meta-analysis[J]. BMC Nephrol, 2019, 20(1):360. doi: 10.1186/s12882-019-1544-2 URL
[34]	Qu Z, Zhang MF, Cui Z, et al. Antibodies against M-type phospholipase A2 receptor may predict treatment response and outcome in membranous nephropathy[J]. Am J Nephrol, 2018, 48(6):1-9. doi: 10.1159/000490625 URL
[35]	Joo SE, Hwa JK, Ae YY, et al. Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy[J]. Kidney Res Clin Pract, 2018, 37(3):248-256. doi: 10.23876/j.krcp.2018.37.3.248 URL
[36]	Hirotaka M, Ken Y, Hirofumi N, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes[J]. Ann Rheum Dis, 2009, 75(4):652-659.
[37]	侯俊英. 抗PLA2R抗体对特发性膜性肾病患者终末期肾病的预测价值[J]. 中国中西医结合肾病杂志, 2020, 21(1):63-65.
[38]	Rodas LM, Matas-García A, Barros X, et al. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy[J]. Clin Kidney J, 2019, 12(1):36-41. doi: 10.1093/ckj/sfy005 pmid: 30747150

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 38

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Tao, Gao Yuwei, Wang Xinghua, Hu Xiuhong, Cui Hongrui, Xu Baozhen, Yang Hongjuan. Correlation of anti-phospholipase A2 receptor antibody with idiopathic membranous nephropathy [J]. Clinical Focus, 2023, 38(7): 606-612.
[2]	Gao Qinyu, Bao Beiyan, Jin Yan, Zhao Yu. Analysis of clinical features and prognostic factors of IgA nephropathy complicated with depression [J]. Clinical Focus, 2023, 38(6): 510-515.
[3]	. [J]. Clinical Focus, 2022, 37(11): 1053-1056.
[4]	Gao Pengli, Chen Lili, Tian Fen, Zhang Jiaqian, Chen Yipeng, Qi Xiaojing, Xing Guangqun. Impact of body mass index in the clinicopathology and prognosis of patients with IgA nephropathy [J]. Clinical Focus, 2022, 37(3): 234-242.
[5]	Liu Jiali, Xie Rong, Li Xuelian, Liu Xiaohui. Correlation analysis between neutrophil/lymphocyte ratio with Lee’s grading and Oxford classification of IgA nephropathy [J]. Clinical Focus, 2021, 36(5): 432-435.
[6]	. [J]. CLINICAL FOCUS, 2013, 28(3): 342-347.
[7]	. [J]. Clinical Focus, 2012, 27(17): 1540-1542.
[8]	GE Xiao;WANG Yan-li;YANG Li-ya;CHEN Jun-feng;LIU Bi-chen. Cyclosporine A treatment for idiopathic membranous nephropathy: a systematic review and Meta-analysis [J]. Clinical Focus, 2012, 27(3): 196-201.
[9]	. [J]. CLINICAL FOCUS, 2010, 25(23): 2100-0.
[10]	. [J]. CLINICAL FOCUS, 2010, 25(18): 1645-1646.
[11]	. [J]. CLINICAL FOCUS, 2009, 24(24): 2161-2162.
[12]	. [J]. CLINICAL FOCUS, 2009, 24(21): 1932-1932.
[13]	. [J]. CLINICAL FOCUS, 2007, 22(21): 1594-0.
[14]	FU Shu-xia;XING Ling-ling;PEI Hua-ying;Li Shao-mei;YANG Lin;WANG Yan. Influencing factors of glucocorticoid-induced insulin resistance and clinic [J]. CLINICAL FOCUS, 2007, 22(16): 1144-1147.
[15]	. [J]. CLINICAL FOCUS, 2006, 21(14): 1034-1035.